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Clinics and pathology 
Disease 
De novo and therapy related leukaemias; acute non 
lymphocytic leukaemia (ANLL) and acute lymphocytic 
leukaemia (ALL) grossly represent half cases each; 
myelodysplasia (MDS) in the remaining 5%; 
biphenotypic leukaemia at times (likely to be more 
frequent with more investigations); 11q23 
rearrangements in treatment related leukaemias (5-10% 
of 11q23 cases) are found mainly following a treatment 
with anti-topoisomerase II, or an intercalating 
topoisomerase II inhibitor, but also after alkylating 
agents treatment and/or radiotherapy; the prior cancer 
is variable. 
Phenotype / cell stem origin 
ANLL: M5a in half cases, M4 (20%), M1 or M5b (10% 
each), M2 (5%); ALL: B-cell mostly, L1 or L2, CD19+ 
in 60% of B-ALL cases, CD10+ 35%; T-ALL in rare 
cases (<1%); MDS: most often RA or RAEB±T. 
Epidemiology 
25% are infant (<1 yr) cases; children and adults each 
represent 50% of cases; M/F = 0.9 (NS). 
Clinics 
Organomegaly; frequent CNS involvement (5%); high 
WBC (> 50 X 109/l in 40%). 
Prognosis 
Very poor in general; variable according to the 
translocation, the phenotype, the age, and whether the 
leukaemia is de novo or secondary. 
Cytogenetics 
Cytogenetics, morphological 
- +11: 1% of ANLL and MDS as well; M1, M2, and 
M4 ANLL; therapy related ANLL; MDS evolving 
towards ANLL; partial tandem duplication (in situ) of
MLL; visible dup(11q) also occur. 
- inv(11)(p15q23): rare; ANLL and MDS. 
- t(X;11)(q13;q23): rare; ANLL; the gene involved in
Xq13 is AFX1, a transcription regulator. 
- t(1;11)(p32;q23): rare; ALL and ANLL; the gene 
involved in 1p32 is AF1P. 
- t(1;11)(q21;q23): rare; mostly M4 ANLL; the gene 
involved in 1q21 is AF1q. 
- t(2;11)(p21;q23): rare; ANLL and MDS; may be 
found associated with del(5q). 
- t(3;11)(p21;q23): very rare; involve AF3p21. 
- t(4;11)(q21;q23): represent 1/3 of cases; found mainly 
(95%) in B-ALL (CD19+ in 75%, CD10+ in 15%); 
treatment related ALL in 5%; unbalanced sex ratio < 4 
yrs (1M/2F); children represent half cases (infants (<1 
yr) accounting for 1/3 of all cases); children aged 2-9 
yrs appear to have a much better prognosis; the gen
involved in 4q21 is AF4, a transcription activator. 
- t(6;11)(q27;q23): 5% of cases; mostly; children and 
young adults; male predominance; the gene involved in 
6q27 is AF6; role in signal transduction. 
- t(9;11)((p23;q23): represent 1/4 of cases; found i  
ANLL mainly in M5a (70%), or M4 (10%); in ALL in 
10%; de novo and therapy related AL; children 
represent half cases (infants (<1 yr) accounting for 15% 
of all cases); the gene involved in 9p22 is AF9, a 
transcription activator. 
- t(10;11)(p12;q23): 5% of cases; M4 or M5 ANLL; 
ALL at times; from infants and children to (rare) adult 
cases; the gene involved in 10p12 is AF10, a 
transcription activator. 
- t(11;16)(q23;p13): rare; treatment related 
ANLL/MDS; most cases are children cases; the gene 
involved in 16p13 is CBP, a transcriptional 
adaptor/coactivator. 
- t(11;17)(q23;q21): rare; ANLL; the gene involved in 
17q21 is AF17; not to be confused with the 
t(11;17)(q23;q21) in M3 ANLL variant, with  
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involvement of PLZF in 11q23 and RARa in 17q21. 
- t(11;17)(q23;q25): rare; ANLL and MDS. 
- t(11;19)(q23;p13.1): 5% of cases; M4 or M5 ANLL 
most often; de novo and therapy related AL; adults 
mainly; the gene involved in 19p13.1 is ELL, a 
transcription activator. 
- t(11;19)(q23;p13.3): 5% of cases; ALL, biphenotypic 
AL and ANLL (M4/M5 mainly); therapy related AL; 
T-cell ALL at times, these T-cell cases are the only 
cases of t(11;19) with an excellent prognosis, a rather 
rare feature in this page!!; mostly found in infants (half 
cases), and other children (altogether: 70%), or young 
adults (cases 40 yrs are 4%; 23 unpublished cases and 
review of 90 cases); the gene involved in 19p13.3 is 
ENL, a transcription activator. 
Various other poorly known 11q23 rearrangements 
have been described: 
- t(5;11)(q31;q23), 
- t(6;11)(q21;q23): ANLL; the gene involved in 6q21 is 








- t(11;22)(q23;q13): ANLL; the gene involved in 22q13 
is P300. 
Various other breakpoints with 11q23 are: Xq22, 1q32, 
2q37, 8q11, 9p11, 9q33, 12p13, 14q11, 14q32, 17q11, 
18q12, 20q13, … 
Additional anomalies 
+X and i(7q) in the t(4;11); +8, +19, +21 in the t(6;11); 
+8 and +19 in the t(9;11); inv(11) in the t(10;11); +X, 
+6 and +8 in the 19p13.3; +8 in the 19p13.1. 
Genes involved and Proteins 
MLL 
Location: in 11q23 
DNA / RNA 
21 exons, spanning over 100 kb; 13-15 kb mRNA; 
coding sequence: 11.9 kb. 
Protein 
431 kDa; contains two DNA binding motifs (a AT 
hook, and Zinc fingers), a DNA methyl transferase 
motif, a bromodomain; transcriptional regulatory 
factor; nuclear localisation; wide expression; homology 
with trithorax (drosophila). 
Variable gene, from a variable 
chromosome partner (see above) 
DNA / RNA 
These genes appear to have, in most cases, no apparent 
homology to each other; for DNA and protein 
description of each, refer to their gene entry. 








N-term AT hook and DNA methyltransferase from 
MLL fused to (little or most of) the partner C-term part; 
the reciprocal (partner-MLL) may or may not be 
expressed. 
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